Mystical and Affective Aspects of Psychedelic Use in a Naturalistic Setting: A Linguistic Analysis of Online Experience Reports

References

• Barrett, F. S., and R. R. Griffiths. 2018. Classic hallucinogens and mystical experiences: Phenomenology and neural correlates. Current Topics in Behavioral Neurosciences 36:393–430. doi:10.1007/7854_2017_474.
   PubMedGoogle Scholar
• Barrett, F. S., M. W. Johnson, and R. R. Griffiths. 2015. Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology 29 (11):1182–90. doi:10.1177/0269881115609019.
   PubMed Web of Science ®Google Scholar
• Barsuglia, J., A. K. Davis, R. Palmer, R. Lancelotta, A. M. Windham-Herman, K. Peterson, M. Polanco, R. Grant, and R. R. Griffiths. 2018. Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study. Frontiers in Psychology 9:2459. doi:10.3389/fpsyg.2018.02459.
   PubMed Web of Science ®Google Scholar
• Boyd, R. L., A. Ashokkumar, S. Seraj, and J. W. Pennebaker. 2022. The development and psychometric properties of LIWC-22. March 31. https://www.liwc.app.
   Google Scholar
• Brandt, P. M., and P. Y. Herzberg. 2020. Is a cover letter still needed? Using LIWC to predict application success. International Journal of Selection and Assessment 28 (4):417–29. doi:10.1111/ijsa.12299.
   Web of Science ®Google Scholar
• Breeksema, J. J., A. R. Niemeijer, E. Krediet, E. Vermetten, and R. A. Schoevers. 2020. Psychedelic treatments for psychiatric disorders: A systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs 34 (9):925–46. doi:10.1007/s40263-020-00748-y.
   PubMed Web of Science ®Google Scholar
• Carbonaro, T. M., M. P. Bradstreet, F. S. Barrett, K. A. MacLean, R. Jesse, M. W. Johnson, and R. R. Griffiths. 2016. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology 30 (12):1268–78. doi:10.1177/0269881116662634.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., L. Roseman, E. Haijen, D. Erritzoe, R. Watts, I. Branchi, and M. Kaelen. 2018. Psychedelics and the essential importance of context. Journal of Psychopharmacology 32 (7):725–31. doi:10.1177/0269881118754710.
   PubMed Web of Science ®Google Scholar
• Cox, D. J., A. Garcia-Romeu, and M. W. Johnson. 2021. Predicting changes in substance use following psychedelic experiences: Natural language processing of psychedelic session narratives. The American Journal of Drug and Alcohol Abuse 47 (4):444–54. doi:10.1080/00952990.2021.1910830.
   PubMed Web of Science ®Google Scholar
• Coyle, J. R., D. E. Presti, and M. J. Baggott. 2012. Quantitative Analysis of narrative reports of psychedelic drugs. Preprint, submitted in. https://arxiv.org/abs/1206.0312.
   Google Scholar
• Davis, A. K., J. M. Clifton, E. G. Weaver, E. S. Hurwitz, M. W. Johnson, and R. R. Griffiths. 2020. Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: Phenomenology, interpretation, and enduring effects. Journal of Psychopharmacology 34 (9):1008–20. doi:10.1177/0269881120916143.
   PubMed Web of Science ®Google Scholar
• Devlin, J., M.-W. Chang, K. Lee, and K. Toutanova. 2018. BERT: Pre-training of deep bidirectional transformers for language understanding. Preprint, Submitted in. https://arxiv.org/abs/1810.04805.
   Google Scholar
• Fauvel, B., S. Kangaslampi, L. Strika-Bruneau, B. Roméo, and P. Piolino. 2023. Validation of a French version of the mystical experience questionnaire with retrospective reports of the most significant psychedelic experience among French users. Journal of Psychoactive Drugs 55 (2):170–79. doi:10.1080/02791072.2022.2059796.
   PubMed Web of Science ®Google Scholar
• Gashi, L., S. Sandberg, and W. Pedersen. 2021. Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences. International Journal of Drug Policy 87:102997. doi:10.1016/j.drugpo.2020.102997.
   PubMed Web of Science ®Google Scholar
• Goodwin, G. M., S. T. Aaronson, O. Alvarez, P. C. Arden, A. Baker, J. C. Bennett, C. Bird, R. E. Blom, C. Brennan, D. Brusch, et al. 2022. Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine 387 (18):1637–48. doi:10.1056/NEJMoa2206443.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., M. W. Johnson, W. A. Richards, B. D. Richards, U. McCann, and R. Jesse. 2011. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology 218 (4):649–65. doi:10.1007/s00213-011-2358-5.
   PubMed Web of Science ®Google Scholar
• Griffiths, R., W. Richards, M. Johnson, U. McCann, and R. Jesse. 2008. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology 22 (6):621–32. doi:10.1177/0269881108094300.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., W. A. Richards, U. McCann, and R. Jesse. 2006. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187 (3):268–83. discussion 284-92. doi:10.1007/s00213-006-0457-5.
   PubMed Web of Science ®Google Scholar
• Haijen, E., M. Kaelen, L. Roseman, C. Timmermann, H. Kettner, S. Russ, D. Nutt, R. E. Daws, A. D. G. Hampshire, R. Lorenz, et al. 2018. Predicting responses to psychedelics: A prospective study. Frontiers in Pharmacology 9:897. doi:10.3389/fphar.2018.00897.
   PubMed Web of Science ®Google Scholar
• Hartogsohn, I. 2018. The meaning-enhancing properties of psychedelics and their mediator role in psychedelic therapy, spirituality, and creativity. Frontiers in Neuroscience 12:129. doi:10.3389/fnins.2018.00129.
   PubMed Web of Science ®Google Scholar
• Hirschfeld, T., and T. T. Schmidt. 2021. Dose-response relationships of psilocybin-induced subjective experiences in humans. Journal of Psychopharmacology 35 (4):384–97. doi:10.1177/0269881121992676.
   PubMed Web of Science ®Google Scholar
• Hood, R. W. 1975. The construction and preliminary validation of a measure of reported mystical experience. Journal for the Scientific Study of Religion 14 (1):29–41. doi:10.2307/1384454.
   Web of Science ®Google Scholar
• Hutto, C., and E. Gilbert. 2014. VADER: A parsimonious rule-based model for sentiment analysis of social media text. Proceedings of the International AAAI Conference on Web & Social Media 8 (1):216–25. doi:10.1609/icwsm.v8i1.14550.
   Google Scholar
• Johnson, M. W., P. S. Hendricks, F. S. Barrett, and R. R. Griffiths. 2019. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics 197:83–102. doi:10.1016/j.pharmthera.2018.11.010.
   PubMed Web of Science ®Google Scholar
• Kahneman, D. 2013. Thinking, fast and slow. New York: Farrar, Straus and Giroux.
   Google Scholar
• Kangaslampi, S., A. Hausen, and T. Rauteenmaa. 2020. Mystical experiences in retrospective reports of first times using a psychedelic in Finland. Journal of Psychoactive Drugs 52 (4):309–18. doi:10.1080/02791072.2020.1767321.
   PubMed Web of Science ®Google Scholar
• Liechti, M. E., P. C. Dolder, and Y. Schmid. 2017. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology 234 (9–10):1499–510. doi:10.1007/s00213-016-4453-0.
   PubMed Web of Science ®Google Scholar
• Lyvers, M., and M. Meester. 2012. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. Journal of Psychoactive Drugs 44 (5):410–17. doi:10.1080/02791072.2012.736842.
   PubMed Web of Science ®Google Scholar
• McCulloch, D. E., M. Z. Grzywacz, M. K. Madsen, P. S. Jensen, B. Ozenne, S. Armand, G. M. Knudsen, P. M. Fisher, and D. S. Stenbaek. 2022. Psilocybin-induced mystical-type experiences are related to persisting positive effects: A quantitative and qualitative report. Frontiers in Pharmacology 13:841648. doi:10.3389/fphar.2022.841648.
   PubMed Web of Science ®Google Scholar
• Miceli McMillan, R., and A. V. Fernandez. 2022. Understanding subjective experience in psychedelic-assisted psychotherapy: The need for phenomenology. Australian & New Zealand Journal of Psychiatry 57:783–88. doi:10.1177/00048674221139962.
   PubMed Web of Science ®Google Scholar
• Python.org. Python 3.8.8. 2023 Feb 19. https://www.python.org/downloads/release/python-388/.
   Google Scholar
• Qiu, T., and J. P. Minda. 2021. Recreational psychedelic users frequently encounter complete mystical experiences: Trip content and implications for wellbeing. Preprint, Submitted in 2021. https://psyarxiv.com/xrbzs/.
   Google Scholar
• Robinson, R. L., R. Navea, and W. Ickes. 2013. Predicting final course performance from students’ written self-introductions. Journal of Language and Social Psychology 32 (4):469–79. doi:10.1177/0261927x13476869.
   Web of Science ®Google Scholar
• Sanz, C., F. Cavanna, S. Muller, L. de la Fuente, F. Zamberlan, M. Palmucci, L. Janeckova, M. Kuchar, F. Carrillo, A. M. Garcia, et al. 2022. Natural language signatures of psilocybin microdosing. Psychopharmacology 239 (9):2841–52. doi:10.1007/s00213-022-06170-0.
   PubMed Web of Science ®Google Scholar
• Sanz, C., F. Zamberlan, E. Erowid, F. Erowid, and E. Tagliazucchi. 2018. The experience elicited by hallucinogens presents the highest similarity to dreaming within a large database of psychoactive substance reports. Frontiers in Neuroscience 12:7. doi:10.3389/fnins.2018.00007.
   PubMed Web of Science ®Google Scholar
• Schimmel, N., J. J. Breeksema, S. Y. Smith-Apeldoorn, J. Veraart, W. van den Brink, and R. A. Schoevers. 2022. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: A systematic review. Psychopharmacology 239 (1):15–33. doi:10.1007/s00213-021-06027-y.
   PubMed Web of Science ®Google Scholar
• Smith, K. W., D. J. Sicignano, A. V. Hernandez, and C. M. White. 2022. MDMA-Assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review with meta-analysis. The Journal of Clinical Pharmacology 62 (4):463–71. doi:10.1002/jcph.1995.
   PubMed Web of Science ®Google Scholar
• Stace, W. T. 1960a. Mysticism and philosophy. New York: MacMillan Press.
   Google Scholar
• Stace, W. T. 1960b. The teachings of the mystics. New York: New American Library.
   Google Scholar
• Tagliazucchi, E. 2022. Language as a window into the altered state of consciousness elicited by psychedelic drugs. Frontiers in Pharmacology 13:812227. doi:10.3389/fphar.2022.812227.
   PubMed Web of Science ®Google Scholar
• Taves, A. 2020. Mystical and other alterations in sense of self: An expanded framework for studying nonordinary experiences. Perspectives on Psychological Science 15 (3):669–90. doi:10.1177/1745691619895047.
   Web of Science ®Google Scholar
• van Elk, M., and D. B. Yaden. 2022. Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. Neuroscience & Biobehavioral Reviews 140:104793. doi:10.1016/j.neubiorev.2022.104793.
   PubMed Web of Science ®Google Scholar
• Zamberlan, F., C. Sanz, R. Martinez Vivot, C. Pallavicini, F. Erowid, E. Erowid, and E. Tagliazucchi. 2018. The varieties of the psychedelic experience: A preliminary study of the association between the reported subjective effects and the binding affinity profiles of substituted phenethylamines and tryptamines. Frontiers in Integrative Neuroscience 12:54. doi:10.3389/fnint.2018.00054.
   PubMed Web of Science ®Google Scholar